SCHEMBL1665178

SCHEMBL1665178

COC(=O)Oc1ccccc1C=O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.58
KDM4E B2RXH2 2/20 0.58
HSD17B10 Q99714 1/20 0.58
ALDH1A1 P00352 4/20 0.52
HTT P42858 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
LMNA P02545 3/20 0.51
PTGDR2 Q9Y5Y4 1/20 0.51
CYP1A2 P05177 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
SRC P12931 2/20 0.50
TLR2 O60603 1/20 0.50
ERN1 O75460 1/20 0.50
TLR1 Q15399 1/20 0.50
TLR6 Q9Y2C9 1/20 0.50
KMT2A Q03164 2/20 0.48
GAA P10253 1/20 0.48
NFE2L2 Q16236 3/20 0.46
NPSR1 Q6W5P4 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8901347 0.89 KDM4E (0.58) HPGDKDM4EHSD17B10ALDH1A1HTT
SCHEMBL1006065 0.88 ALDH1A1 (0.59) HPGDKDM4EHSD17B10ALDH1A1HTT
SCHEMBL21579710 0.86 ERN1 (0.67) HPGDKDM4EHSD17B10ALDH1A1HTT
SCHEMBL7542596 0.85 KDM4E (0.54) HPGDKDM4EHSD17B10ALDH1A1HTT
SCHEMBL1665175 0.84 PTGDR2 (0.51) HPGDKDM4EHSD17B10ALDH1A1HTT
SCHEMBL11925422 0.83 KDM4E (0.70) HPGDKDM4EHSD17B10ALDH1A1HTT
SCHEMBL13799146 0.83 SLC6A3 (0.58) HPGDKDM4EHSD17B10ALDH1A1HTT
SCHEMBL26667032 0.81 GAA (0.60) HPGDKDM4EHSD17B10HTTSMN1; SMN2
SCHEMBL31236265 0.81 PTGDR2 (0.53) HPGDKDM4EHSD17B10ALDH1A1HTT
SCHEMBL1665129 0.81 SRC (0.59) HPGDKDM4EALDH1A1LMNACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113750917-B High-elasticity high-temperature-resistant aerogel and preparation method thereof 刘建浩 2024-05-03 CN claimed
CN-117509602-A Preparation method of high-elasticity high-temperature-resistant aerogel 刘建浩 2024-02-06 CN claimed
CN-113750917-A High-elasticity high-temperature-resistant aerogel and preparation method thereof 刘建浩 2021-12-07 CN claimed
CN-113750917-B High-elasticity high-temperature-resistant aerogel and preparation method thereof 刘建浩 2024-05-03 CN disclosed
CN-113750917-B High-elasticity high-temperature-resistant aerogel and preparation method thereof 刘建浩 2024-05-03 CN disclosed
CN-117509602-A Preparation method of high-elasticity high-temperature-resistant aerogel 刘建浩 2024-02-06 CN disclosed
CN-117509602-A Preparation method of high-elasticity high-temperature-resistant aerogel 刘建浩 2024-02-06 CN disclosed
CN-113750917-A High-elasticity high-temperature-resistant aerogel and preparation method thereof 刘建浩 2021-12-07 CN disclosed
CN-113750917-A High-elasticity high-temperature-resistant aerogel and preparation method thereof 刘建浩 2021-12-07 CN disclosed
EP-2493905-B1 BISPHOSPHONATE COMPOUNDS FOR TREATING BONE METABOLISM DISORDERS WARNER CHILCOTT CO LLC (PR) 2016-11-30 EP disclosed
US-8822435-B2 Bisphosphonate compounds WARNER CHILCOTT COMPANY, LLC (US) 2014-09-02 US disclosed
US-8710215-B2 Bisphosphonate compounds WARNER CHILCOTT COMPANY, LLC (US) 2014-04-29 US disclosed
US-20130035482-A1 BISPHOSPHONATE COMPOUNDS WARNER CHILCOTT COMPANY, LLC (US) 2013-02-07 US disclosed
US-8314081-B2 Bisphosphonate compounds WARNER CHILCOTT COMPANY, LLC (US) 2012-11-20 US disclosed
EP-2493905-A1 BISPHOSPHONATE COMPOUNDS FOR TREATING BONE METABOLISM DISORDERS Warner Chilcott Company, LLC (PR) 2012-09-05 EP disclosed
WO-2011056589-A1 BISPHOSPHONATE COMPOUNDS FOR TREATING BONE METABOLISM DISORDERS WARNER CHILCOTT COMPANY, LLC (US) 2011-05-12 WO disclosed
US-20110098251-A1 BISPHOSPHONATE COMPOUNDS WARNER CHILCOTT COMPANY, LLC (US) 2011-04-28 US disclosed
EP-0907633-B1 NEW SYNTHETIC CATECHOL DERIVATIVES, METHOD FOR PRODUCTION AND USE THEREOF GRUENENTHAL GMBH (DE) 2001-08-22 EP disclosed
EP-0907633-A1 NEW SYNTHETIC CATECHOL DERIVATIVES, METHOD FOR PRODUCTION AND USE THEREOF Grünenthal GmbH (DE) 1999-04-14 EP disclosed
WO-1997049670-A1 NEW SYNTHETIC CATECHOL DERIVATIVES, METHOD FOR PRODUCTION AND USE THEREOF Grünenthal GmbH (DE) 1997-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098251-A1 BISPHOSPHONATE COMPOUNDS BPGM, PPIP5K2, PTEN HPGD 358/4885KDM4E 2687/4885HSD17B10 1675/4885
US-20130035482-A1 BISPHOSPHONATE COMPOUNDS BPGM, PPIP5K2, PTEN HPGD 358/4885KDM4E 2687/4885HSD17B10 1675/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.